Breast cancer and lymphoma are both major types of cancer frequently studied in the context of precision medicine, targeted therapy, and synthetic lethality clinical trials, as evidenced by [1], [2], [3], [4], and [5]. Furthermore, both conditions involve specific diagnostic testing for gene or protein changes [6] and are categorized within broader research frameworks regarding DNA damage response and non-DDR pathways [7], [8].